Laura Francis Sells 3,923 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 3,923 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $20.02, for a total transaction of $78,538.46. Following the sale, the chief executive officer owned 317,463 shares of the company’s stock, valued at $6,355,609.26. The trade was a 1.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Laura Francis also recently made the following trade(s):

• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The shares were sold at an average price of $19.46, for a total value of $1,009,662.64.

SiBone Stock Up 2.5%

NASDAQ:SIBN opened at $19.96 on Friday. SiBone has a 12-month low of $11.48 and a 12-month high of $21.89. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $885.23 million, a P/E ratio of -58.71 and a beta of 0.66. The stock’s fifty day simple moving average is $17.49 and its 200-day simple moving average is $15.33.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million during the quarter, compared to analysts’ expectations of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. Equities research analysts expect that SiBone will post -0.4 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. Truist Financial reiterated a “buy” rating and issued a $23.00 price target (up from $21.00) on shares of SiBone in a research report on Tuesday, August 4th. TD Cowen lifted their price objective on shares of SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Finally, UBS Group boosted their price objective on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $24.17.

Institutional Investors Weigh In On SiBone

A number of hedge funds have recently modified their holdings of the business. Royal Bank of Canada lifted its holdings in shares of SiBone by 98.5% during the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after purchasing an additional 736 shares in the last quarter. Versant Capital Management Inc grew its position in shares of SiBone by 102.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after purchasing an additional 887 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in SiBone by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after purchasing an additional 1,053 shares in the last quarter. Larson Financial Group LLC increased its stake in SiBone by 42.3% during the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock worth $70,000 after purchasing an additional 1,061 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in SiBone by 4.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,159 shares of the company’s stock worth $733,000 after purchasing an additional 1,459 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

About SiBone

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.